Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million

16 hours ago 1

Jonathan Ponciano, The Motley Fool

Tue, February 3, 2026 astatine 8:21 AM CST 4 min read

Privium Fund Management reported a merchantability of 75,747 shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) successful a February 2 SEC filing, with the estimated commercialized worth astatine $3.71 cardinal based connected quarterly mean pricing.

According to a SEC filing dated February 2, Privium Fund Management reduced its presumption successful Arrowhead Pharmaceuticals by 75,747 shares successful the 4th quarter. The estimated worth of this stock merchantability was $3.71 million, based connected the mean unadjusted closing terms during the quarter. Meanwhile, the quarter-end worth of the fund's Arrowhead presumption surged by $10.09 cardinal arsenic prices likewise skyrocketed, reflecting some trading and terms movement.

Following the sale, Arrowhead represents 4.87% of Privium’s 13F U.S. equity AUM.

Top holdings aft the filing:

NASDAQ: TSLA: $102.76 cardinal (18.9% of AUM)
NASDAQ: SHOP: $66.00 cardinal (12.2% of AUM)
NYSE: SPOT: $39.49 cardinal (7.3% of AUM)
NASDAQ: PLTR: $35.55 cardinal (6.5% of AUM)
NASDAQ: AMZN: $27.93 cardinal (5.1% of AUM)

As of February 2, Arrowhead shares were priced astatine $73.00, up a staggering 289.5% implicit the anterior twelvemonth and vastly outperforming the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Revenue (TTM)	$829.45 million
Net Income (TTM)	($1.6 million)
Market Capitalization	$10.22 billion
Price (as of 2/2/26)	$73.00

Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics targeting diseases specified arsenic liver disorders, hypertriglyceridemia, complement-mediated diseases, and uncommon familial conditions, with a portfolio spanning aggregate objective phases.
The institution generates gross chiefly done the development, licensing, and collaboration of proprietary RNAi cause candidates, leveraging strategical partnerships with large pharmaceutical firms to monetize pipeline assets and beforehand objective programs.
It serves pharmaceutical companies and healthcare providers focused connected treating patients with intractable and uncommon diseases, peculiarly successful the United States and planetary biopharmaceutical markets.

Arrowhead Pharmaceuticals, Inc. is simply a biotechnology institution specializing successful RNAi-based therapeutics for superior and uncommon diseases. The institution leverages a robust clinical-stage pipeline and strategical collaborations with starring pharmaceutical partners to thrust innovation and accelerate commercialization. Its standard and absorption connected caller RNAi modalities presumption it arsenic a competitory subordinate wrong the biotechnology sector.

Arrowhead conscionable crossed a enactment that not each clinical-stage biotechs reach. In November, the FDA approved REDEMPLO, the company’s archetypal commercialized cause and the archetypal siRNA therapy approved for familial chylomicronemia syndrome. That milestone reshaped the financials. Fiscal 2025 gross surged to $829 cardinal from $3.6 cardinal 1 twelvemonth earlier, driven mostly by licensing and milestone payments, and operating income swung to a $98 cardinal nett from a steep nonaccomplishment of $612 cardinal a twelvemonth earlier. Total currency resources ended the twelvemonth astatine $782 million, giving Arrowhead flexibility arsenic it builds a commercialized motor and advances a heavy pipeline.

The banal responded accordingly, climbing astir 60% since the net merchandise and astir 290% twelvemonth implicit year. Against that backdrop, trimming portion keeping Arrowhead astatine 4.9% of AUM looks similar hazard control, not doubt. This portfolio already leans heavy into high-beta winners similar Tesla, Shopify, and Palantir. With that successful mind, locking successful immoderate gains portion preserving upside vulnerability fits a strategy built astir momentum with guardrails. For semipermanent investors, the awesome is assurance with discipline.